Boehringer skeleton to plea lung cancer drugs

<p>CHICAGO (Reuters) – German drug association <span>Boehringer Ingelheim</span> pronounced on Monday it would exam a initial <span>lung cancer drug</span> directly opposite <span>AstraZeneca</span>‘s Iressa and Roche’s Tarceva pill, after it showed guarantee in a late-stage drug trial.</p>
<p> A investigate showed Boehringer’s afatinib drug enlarged a time <span>lung cancer patients</span> survived but a worsening of their condition by 4.2 months on normal when compared with a control organisation on customary <span>chemotherapy</span>.</p>
<p> Results of a investigate were presented during a annual association of a <span>American Society for Clinical Oncology</span> in Chicago on Sunday.</p>
<p> “This really meets a expectations. It’s really encouraging,” pronounced Dr. <span>Lecia Sequist</span>, an oncologist during Mas...